Identification of a large class of cancer-germline microproteins as a source of immunotherapeutic targets
Classical cancer germline-antigens (CGAs) are proteins that are expressed in the male germinal line but not in somatic tissues, and that can also become expressed in tumors. However, the vast majority of testis-specific transcripts are long non-coding RNAs (lncRNAs) rather than protein-coding genes. Since recent studies have shown that many lncRNAs contain non-canonical open reading frames (ncORFs) that are translated into small proteins, or microproteins, there could be a large class of non-canonical cancer-germline antigens (ncCGAs) that remains to be discovered. Here, we integrate ribosome profiling from human testis and cancer cell lines with paired tumor/normal transcriptomes from 917 patients across eight common cancer types to define a comprehensive catalog of ncCGAs. This set comprises 235 ncCGAs encoded by lncRNAs or mRNA untranslated regions (5UTRs and 3UTRs), compared to 192 canonical CGAs (cCGAs) with similar expression patterns. We show that ncCGAs are evolutionary young, consistent with recent de novo emergence in the rapidly evolving male germline. Moreover, a large fraction is expressed across multiple patients and cancer types, indicating recurrent reactivation mechanisms in tumors. We further find that ncCGAs are frequently located in cancer-amplified regions or associated with MYC or E2F-regulated pathways, which may explain their expression in cancer. Finally, we provide strong evidence that a subset of ncCGAs give rise to potentially immunogenic HLA class I bound peptides. Together, our results describe a previously unexplored class of tumor-restricted antigens with potential applications in cancer immunotherapy.